Breaking News on Biopharmaceutical Development & Manufacturing

Headlines > Bio Developments

A cracking new method: Valneva and Bavarian Nordic’s hen egg alternative

21-Apr-2017 - European biotech companies Valneva and Bavarian Nordic have entered a commercial agreement to develop cell-based vaccines using production methods that are faster and cheaper than methods that use hen’s eggs. ...

News in brief

Synpromics announces £5.2M British investment in gene therapy tech

19-Apr-2017 - Scottish synthetic biology firm Synpromics has received £5.2M ($6.6M) to enhance its synthetic promoter design technology used in gene therapy development.

1st Stem Cell Community day in Germany

For stem cells 'the process is the product,' says Pluristem

19-Apr-2017 - Manufacturing tweaks have severe effects on the quality and yield of stem cells, says Pluristem which has successfully scaled-up production through a decade of process development evolution.

Pork firm Smithfield sets up organ supply unit for regenerative meds sector

13-Apr-2017 - Smithfield Foods Inc. has tasked a new bioscience unit with turning byproducts from its pork business into supplies for regenerative meds and drug firms.

Sanfilippo syndrome gene therapy could be filed in US next year, Abeona

11-Apr-2017 - Abeona Therapeutics says it plans to file its single injection adeno-associated virus (AAV) gene therapy for Sanfilippo syndrome in the US in late 2018.

RESPECT: find out what it means to ADCs, says Eisai subsidiary

07-Apr-2017 - Morphotek Inc has launched an antibody-drug conjugate (ADC) services business incorporating its RESPECT site-specific conjugation technology and eribulin-linker toxin platform.

Shire success will support polysialic acid drug delivery platform, says Xenetic

06-Apr-2017 - Xenetic Biosciences says success for Shire’s haemophilia A candidate SHP656 will validate its PolyXen drug delivery technology platform and could net the firm up to $100m.

Stem cell community meets in Hamburg

04-Apr-2017 - is at @Eppendorf_AG 's stem cell community day in Hamburg, Germany. Here is a collection of tweets sent from the conference.

US FDA submissions pit Novartis and Kite head-to-head in CAR race

04-Apr-2017 - Novartis and Kite Pharma have both submitted autologous leukemia candidates for review, paving the road for the first available chimeric antigen receptor (CAR) T cell therapy.

UK biotech inks stem cell engineering deal with Singapore researchers

31-Mar-2017 - Plasticell has partnered with Singapore’s Agency for Science, Technology and Research (A*STAR) and the Nanyang Technological University (NTU) to advance its stem cell pipeline.

Emisphere set to benefit as Novo Nordisk pushes oral diabetes pipeline

30-Mar-2017 - Novo Nordisk’s focus on developing oral versions of semaglutide and four other diabetes drugs could net drug delivery firm Emisphere over $200m.

Eleven Biotherapeutics: Taking on ADCs with targeted protein therapeutics

28-Mar-2017 - A two-step manufacturing process makes antibody-drug conjugate production expensive and causes stability issues, says Eleven Biotherapeutics which is fusing antibody fragments to cytotoxic proteins.

Eurofins pumping $5m into a UK biopharmaceutical testing site

24-Mar-2017 - Eurofins will expand its UK biopharmaceutical testing offering through a £4m ($5m) facility in Livingston, Scotland.

US FDA fast-track designation for Humacyte's tissue-based hemodialysis product

22-Mar-2017 - Humacyte has received one of the first US FDA regenerative medicine designations for its investigational human acellular vessels (HAVs) candidate Humacyl.

Goodwin Biotech to work on opioid addiction vaccines project

22-Mar-2017 - Contract manufacturer Goodwin Biotechnology will work with Minneapolis Medical Research Foundation (MMRF) to develop vaccines to treat opioid addiction.

Lonza launches liver cells for biopharma research

17-Mar-2017 - Lonza has launched a new range of cryopreserved liver cells for biopharmaceutical companies that want to assess the toxicity of their drugs.

CDMO 3P selected to scale-up microbial production for Aussie biotech

14-Mar-2017 - Assuring anaerobic conditions in a fermenter design for aerobic organisms will be key in making Ondek’s Helicobacter pylori-based immunotherapy, says 3P Biopharmaceuticals.

Pfizer mulls sites for NC gene therapy plant year after Bamboo buy

10-Mar-2017 - Pfizer has confirmed it assessing potential sites in North Carolina for a gene therapy production plant.

Biodefense: Canada develops novel live virus smallpox vaccine from horsepox

07-Mar-2017 - Canada-based Tonix Pharmaceuticals has developed a novel live-virus vaccine for smallpox, which the firm claims is a safer alternative for biodefense stockpiles.

Kite public offering looks to raise $350m for CAR T cell therapy support

07-Mar-2017 - Kite Pharma has announced a public offering to support commercialisation of its lead CAR-based therapy, axicabtagene ciloleucel.

Vaxess granted $6m to develop sustained release vaccine patches

07-Mar-2017 - Two Bill & Melinda Gates Foundation grants will be used to develop a polio and measles rubella vaccine delivered through microneedles on a sustained-dermal patch.

Sartorius ups bioanalysis business with $320m Essen acquisition

03-Mar-2017 - Sartorius’ third acquisition in the bioanalysis space in the past year will add Essen BioScience’s real-time live-cell analysis platform to its portfolio.

UK makes validated stem cells available to therapy developers for £500 per vial

01-Mar-2017 - Cell therapy developers can source “regulator ready” stem cells from the UK Stem Cell Bank (UKSCB) for a £500 per vial fee under a scheme announced by the MHRA.

BioMarin building CA plant to support Factor VIII gene therapy candidate

28-Feb-2017 - A Californian manufacturing facility to support clinical development of a haemophilia A gene therapy will be completed this year, says BioMarin.

Sanofi and Lonza JV to build 200 person biologics facility in Visp

27-Feb-2017 - Sanofi and Lonza will construct a large-scale mammalian cell culture manufacturing site in Switzerland, with an initial investment of CHF 290m ($288m).

Key Industry Events


Access all events listing

Our events, Shows & Conferences...